Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Collegium Pharmaceutical Inc COLL

Healthcare Biotechnology
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed... see more

Recent & Breaking News (NDAQ:COLL)

Collegium Announces Underwriters’ Exercise of Option to Purchase Additional Shares

GlobeNewswire November 29, 2016

Independent Review of Xtampza® ER Published in Peer-Reviewed Medical Journal

GlobeNewswire November 21, 2016

Collegium to Present at Upcoming Investor Conferences

GlobeNewswire November 11, 2016

Collegium Reports Third Quarter Financial Results and Provides Corporate Update

GlobeNewswire November 10, 2016

Collegium to Host Conference Call to Discuss Third Quarter 2016 Financial Results and Provide Corporate Update

GlobeNewswire November 2, 2016

Collegium Prices Public Offering of $80 million of Common Stock

GlobeNewswire October 26, 2016

Collegium Announces Proposed Public Offering of Common Stock

GlobeNewswire October 25, 2016

Collegium Submits Supplemental New Drug Submission to FDA for Xtampza® ER

GlobeNewswire October 5, 2016

Collegium Submits New Drug Submission to Health Canada for Xtampza® ER, an Analgesic with Abuse-Deterrent Properties for the Treatment of Chronic Pain

GlobeNewswire October 3, 2016

18 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  October 3, 2016

15 Biggest Mid-Day Gainers For Friday

Benzinga.com  September 30, 2016

Collegium Announces Publication of Data on Oral Abuse Potential of Xtampza ER

GlobeNewswire September 29, 2016

15 Biggest Mid-Day Gainers For Thursday

Benzinga.com  September 22, 2016

Review of Xtampza® ER Published in The Journal of the American Medical Association

GlobeNewswire September 9, 2016

Collegium to Present at the BioCentury NewsMakers Conference

GlobeNewswire September 7, 2016

Collegium Announces the Launch of OpioidIQ

GlobeNewswire September 6, 2016

Collegium Announces Scientific Presentations at PAINWeek 2016 Meeting

GlobeNewswire September 1, 2016

Collegium Announces Publication of Data on Alternative Modes of Administration of Xtampza ER

GlobeNewswire August 16, 2016

Adherium to Supply AstraZeneca Australia With Smartinhaler™ Platform for a Joint Commercial Pilot Program

GlobeNewswire August 16, 2016

Collegium Reports Second Quarter Financial Results and Provides Corporate Update

GlobeNewswire August 10, 2016